Dunhill Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Dunhill Financial’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22	Hold	2	–	–	﹤0.01%	1582
2026 Q1	$21	Hold	2	–	–	﹤0.01%	1759
2025 Q4	$18	Buy	+2	New	+$14	﹤0.01%	1923

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Dunhill Financial's BCRX Position: Q2 2026 in Review

Dunhill Financial held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 2 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #1582.

Dunhill Financial first reported a position in BCRX in Q4 2025 and has held it in 3 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Dunhill Financial held 2 shares of BioCryst Pharmaceuticals worth $22 as of Q2 2026.
Dunhill Financial left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1582 holding.
Dunhill Financial first reported a position in BioCryst Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.